NLRP3 and metabolic dysfunction-associated steatohepatitis: In 2018, Genentec acquired San Diego-based Jecure Therapeutics and their portfolio of preclinical NLRP3 inhibitors as a treatment for NASH and hepatic fibrosis [199].